We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Vinegar Co-ingestion in Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01279317
Recruitment Status : Completed
First Posted : January 19, 2011
Results First Posted : October 3, 2011
Last Update Posted : October 3, 2011
Information provided by (Responsible Party):
Maastricht University Medical Center

Brief Summary:
The main objective of this study is to assess the acute effect of co-ingested vinegar on postprandial plasma glucose levels in type 2 diabetes patients.

Condition or disease Intervention/treatment
Type 2 Diabetes Mellitus Dietary Supplement: placebo co-ingestion Dietary Supplement: vinegar co-ingestion

Detailed Description:
Plasma glucose and insulin concentrations are assessed over the 2 hr period following ingestion of carbohydrate-rich beverage with or without added vinegar.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Vinegar Co-ingestion on Postprandial Glucose Control in Type 2 Diabetes Patients
Study Start Date : September 2010
Primary Completion Date : March 2011
Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: vinegar co-ingestion
25 ml vinegar is added to glucose containing beverage
Dietary Supplement: vinegar co-ingestion
25 ml vinegar (1 g acetic acid) co-ingested with a glucose-containing beverage
Other Names:
  • vinegar
  • acetic acid
Placebo Comparator: Placebo co-ingestion
25 ml vinegar is substituted by 25 ml water
Dietary Supplement: placebo co-ingestion
25 ml water co-ingested with a glucose-containing beverage

Primary Outcome Measures :
  1. Postprandial Glycemic Incremental Area Under the Curve [ Time Frame: 2 hr ]
    area under the plasma glucose concentration curve, above the baseline plasma glucose, measured over 2 hr following ingestion of a the intervention beverages

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • male type 2 diabetes
  • overweight or obese
  • 40-70 yrs

Exclusion Criteria:

  • incident cardiovascular events during last year
  • peptic ulcer, duodenal ulcer, oesophageal reflux
  • antacids, H2 receptor blocker, proton pump inhibitors, NSAIDS, prokinetic agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01279317

Maastricht University Medical Centre
Maastricht, Limburg, Netherlands, 6200 MD
Sponsors and Collaborators
Maastricht University Medical Center

Responsible Party: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT01279317     History of Changes
Other Study ID Numbers: MEC 10-3-035
First Posted: January 19, 2011    Key Record Dates
Results First Posted: October 3, 2011
Last Update Posted: October 3, 2011
Last Verified: August 2011

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Retinol acetate
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Anticarcinogenic Agents
Protective Agents
Antineoplastic Agents